What the ASPS position statement on pediatric gender surgery actually says — and what it means. A listener’s guide to our episode for March 21 2026; names, the history, and what’s at stake. On February 3, 2026, the American Society of Plastic Surgeons issued a nine-page position statement recommending that surgeons delay all gender-related surgery — breast/chest, genital, and facial — until a patient is at least 19 years old. It was the first statement of its kind from a major American medical association, and the reverberations were immediate. This is a significant moment. Not because it ends the debate, but because it marks the first formal fracture in the wall of institutional consensus that has, for the better part of a decade, treated surgical intervention in minors as settled, evidence-based, and beyond reproach. It was not settled. It was not evidence-based. And the ASPS has now said so on the record. This episode of Informed Dissent features our interview with Dr. Scot Glasberg — a past president of the ASPS and a central figure in the multi-year deliberation that led to this statement. His name, and several others, will come up throughout the conversation. This piece is your guide to who these people are, what their relationships are to each other, and why the internal story of how this statement came to exist is as important as the statement itself. The Organization and Its Reach The ASPS is not a minor player. It represents more than 11,000 physician members and over 90 percent of board-certified plastic surgeons practicing in the United States and Canada. Crucially, plastic surgeons are the primary specialty performing mastectomies on minors with gender dysphoria — approximately 1,000 or more annually in recent years, by conservative estimates. When the ASPS speaks on this issue, it is speaking as the guild whose members have been performing these procedures. That is what makes this statement different from outside criticism. These are the surgeons. What the Statement Actually Says The coverage has focused on the age cutoff — 19 — but the statement goes considerably further. The ASPS doesn’t just recommend delay. It raises foundational questions about the entire treatment pathway. The statement is unambiguous: it characterizes the research supporting gender-related interventions in minors as “low quality/low certainty.” It draws on the 2024 Cass Review commissioned by NHS England, several European systematic reviews, and the HHS report Treatment for Pediatric Gender Dysphoria: Review of Evidence and Best Practices, published in 2025. The statement finds “insufficient evidence demonstrating a favorable risk-benefit ratio for the pathway of gender-related endocrine and surgical interventions in children and adolescents.” Not just surgical interventions. The full pathway — endocrine and surgical — fails the evidence test. The statement also addresses the natural history of gender dysphoria directly: among children, the vast majority show resolution without medical intervention. Among adolescents, existing evidence suggests most will desist as well. This directly challenges the clinical framing that has driven urgent intervention — the idea that the trajectory of a child’s gender identity is fixed and must be medically affirmed. The ASPS also explicitly rejects the “suicide narrative” — the claim that withholding or delaying these interventions is equivalent to causing a child’s death. The statement treats crisis-based justifications for irreversible procedures as a reason for greater caution, not less. On informed consent, the statement is clear: plastic surgeons cannot treat a prior referral letter, a mental health clearance, or a prior medical intervention as a proxy for surgical indication. Each surgeon bears independent professional responsibility to assess the risk-benefit profile — and to communicate uncertainty honestly. Before the Statement: The Cass Review Panel That Never Happened To understand why this statement exists, you have to go back to the fall of 2024. Dr. Scot Glasberg, then president of the Plastic Surgery Foundation — the ASPS’s research wing — had organized a panel at the ASPS annual meeting titled “Translating Evidence into Best Practices: A Gender Medicine and Surgery Paradigm.” Dr. Hilary Cass, author of the landmark 2024 independent review of gender identity services for children commissioned by NHS England, had been invited to present. Before the meeting, a group of ASPS members — including gender surgery practitioners and leaders of gender-affirming surgery programs, among them Dr. Blair Peters — sent a letter to the ASPS board. Their demand: arrange virtual attendance for members who would be at the WPATH conference in Lisbon, Portugal, held simultaneously. The ASPS board met the demands. And then pulled the panel anyway. Every other gender-related session at the annual meeting proceeded as scheduled. The Cass panel was the only one removed. Glasberg sent the notice describing it as “postponed.” The Gender Surgery Task Force was established in May 2025, in part as a response to this episode. Its stated mandate was not to issue guidance, but to seek “areas of emerging consensus” among clinicians with differing perspectives. What no one outside the ASPS initially knew: several members of that task force held simultaneous leadership positions at WPATH — the organization whose standards of care the Cass Review had found to “lack developmental rigour.” The Gender Surgery Task Force’s response to the ASPS statement would become a flashpoint of controversy. The Internal Fracture When the ASPS board released its position statement on February 3, 2026, it did not go through the task force. The board acted independently. The task force — including its WPATH-affiliated members — found out when everyone else did. Seven task force members sent an open letter to the ASPS board demanding transparency about the statement’s authorship and development. The letter was spearheaded by Dr. Jens Berli and subsequently posted publicly on LinkedIn by Dr. Scott Leibowitz — a move that created additional friction within the task force, with at least one member seeking to withdraw his signature. The open letter did not dispute the evidentiary findings. It focused on process. But the identities of its signatories — which include WPATH’s current president, president-elect, and a board member — tell their own story about who had a stake in the task force’s approach and why the board chose to circumvent it. The Malpractice Context The same week the ASPS statement was released, a former patient named Fox Varian was awarded $2 million in a malpractice judgment in New York state after undergoing a double mastectomy as a minor and subsequently detransitioning. It was the first detransitioner lawsuit in the United States to reach a jury verdict. The attorney who represented her, Adam Deutsch, said publicly that the ASPS statement validated his theory of the case: that a surgeon cannot simply defer to a mental health referral when assessing whether an irreversible procedure is appropriate for an adolescent. At least 27 other detransitioner lawsuits are currently pending. The liability calculus for surgeons in this space has changed. What Other Medical Organizations Said The response from other major medical bodies was revealing in its awkwardness. The AMA told reporters it agreed that surgical interventions for minors should be generally deferred to adulthood — but framed this as a clarification of its existing position, not a response to ASPS. The American Academy of Pediatrics said it “does not include a blanket recommendation for surgery for minors” — language that carefully elides what its own guidelines say about supporting surgical interventions for minors on a case-by-case, individualized basis. These organizations have staked significant credibility on a position the evidence no longer supports. The ASPS has now made that visible. Who’s Who: A Listener’s Guide Several names come up throughout this episode. Here is a brief guide to who they are and how they connect to this story. Dr. Scot Glasberg Past President, ASPS | President, Plastic Surgery Foundation | Co-chair, ASPS Gender Surgery Task Force Private practice, Manhattan | Informed Dissent guest, this episode Glasberg convened the Hilary Cass panel at the 2024 ASPS annual meeting that was pulled under pressure from WPATH-aligned members. He was central to the multi-year evidence deliberation inside ASPS that preceded the February 2026 position statement, though he was not involved in the board’s final drafting. He has spoken publicly about the evidentiary basis for the age-19 threshold and the statement’s independence from political pressure. Dr. Hilary Cass Author, the Cass Review (2024) NHS England — Independent Review of Gender Identity Services for Children and Young People Dr. Cass led the most comprehensive independent review of pediatric gender medicine to date, commissioned by NHS England. Her 2024 final report found the evidence base for hormonal and surgical interventions in minors to be “remarkably weak” and found that existing clinical guidelines — including WPATH’s — lacked developmental rigour. She was invited to present at the 2024 ASPS annual meeting and was disinvited when the panel was pulled. The ASPS position statement cites her review approvingly by name. Dr. Loren Schechter President-Elect, WPATH | Member, ASPS Gender Surgery Task Force | Open Letter Signatory Medical Director, Gender Affirmation Surgery Program, Rush University Medical Center, Chicago One of the highest-volume gender surgery practitioners in the U.S. — approximately 100–150 procedures annually. An ASPS member, signatory of the task force open letter, and WPATH’s incoming president. Part of the group that pressured the ASPS board
